Clalit hospitals to stop using Similac in prenatal units

September 21, 2007 08:18


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Clalit Health Fund has decided to stop using Similac formula in all its hospitals' prenatal units after the Health Ministry announced Thursday that it suspected the formula was making some of the premature babies in Beersheba's Soroka Hospital sick. However, the ministry had no hard data to support its suspicion. Soroka's Prof. Ehud Zmora said that mothers who purchase Similac have no cause to worry, as the hospital's product was a special version of the formula designed for premature infants and was not available commercially. A Similac company spokesperson said that the firm stood by its product's quality, as it had been thoroughly tested and approved by the Health Ministry.

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia